ERBB2 and breast cancer: ACE inhibitors and BB were associated with increased cardiotoxicity-free survival and fewer interruptions in cancer therapy compared to placebo among HER2 positive breast cancer patients treated with trastuzumab (± anthracyclines) [4, 8].